Abstract: The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Primary Hyperoxaluria Type 1 (PH1). The present application also provides materials and methods for editing an AGXT gene in a cell by genome editing. The present application also provides materials and methods for altering a contiguous genomic sequence of an AGXT gene in a cell. In addition, the present application provides one or more gRNAs for editing an AGXT gene. The present application also provides a therapeutic comprising at least one or more gRNAs for editing an AGXT gene. In addition, the present application provides a therapeutic for treating a patient with an AGXT related condition or disorder.

Abstract: A first test case identifier that indicates a first test case is received. The first test case is indicative of testing one or more features of an application associated with the electronic marketplace. The first test case identifier is compared to a plurality of attributes. The plurality of attributes are associated with one or more listings that describe one or more items for sale in an electronic marketplace. Based at least in part on the comparing, it is determined that a first set of attributes, of the plurality of attributes, are test data candidates to be used as input to the first test case. Based at least in part on the determining, the first test case is caused to be run using at least one of the first set of attributes as test data for input.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN1 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA1). Also provided are materials and methods for editing a ATXN1 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN1 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN1 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN1 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN1 related condition or disorder.

Abstract: Automated determination of web page rendering performance techniques and systems are described. In one example, a web page including multiple user-interactive elements that can be selected or navigated via user input is received. A frame rendering system is employed to automatically identify the user-interactive elements and generate scripts to simulate user input at the user-interactive elements. The generated scripts are then used to simulate user input at the user-interactive elements. The scripts may be generated to simulate user interaction via a variety of different device types, and under a variety of different network conditions. During the simulation, a rendering performance score for the web page is generated by monitoring rendering performance relative to a threshold rendering rate.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo. In addition, the present disclosure provides materials and methods for editing and/or modulating the expression of SOD1 gene in a cell by genome editing.

Abstract: Automated determination of web page rendering performance techniques and systems are described. In one example, a web page including multiple user-interactive elements that can be selected or navigated via user input is received. A frame rendering system is employed to automatically identify the user-interactive elements and generate scripts to simulate user input at the user-interactive elements. The generated scripts are then used to simulate user input at the user-interactive elements. The scripts may be generated to simulate user interaction via a variety of different device types, and under a variety of different network conditions. During the simulation, a rendering performance score for the web page is generated by monitoring rendering performance relative to a threshold rendering rate.

Abstract: Method and system for revenue maximization in a communication network. This invention relates to management of communication networks and more particularly to monitoring information of a subscriber of a communication network. Embodiments herein enable the network operator to collect and profile usage information of a subscriber on a User Equipment (UE) with the intention of using the information for revenue maximization applications and preventing fraud for a network operator, wherein revenue maximization applications include but are not limited to fraud management, revenue assurance, churn management, customer experience management, credit risk management and partner settlement.

Abstract: A method of determining a return option for a customer of a retail enterprise. The method includes receiving a request to return a previously-ordered inventory item. The request includes item attributes including an item description and an item cost of the previously-ordered inventory item. Customer attributes are received, which include a customer profile, historical sales order metrics, and historical return metrics from a customer attribute database. A risk score for the customer is determined. The risk score is based, at least in part, on the customer attributes and one or more rules assessed by a customer risk assessment tool of the retail enterprise. Based on the risk score and the item attributes, at least one return processing option for the customer is automatically determined. The at least one return processing option is presented to the customer for selection.

Abstract: Method and system for revenue maximization in a communication network. This invention relates to management of communication networks and more particularly to monitoring information of a subscriber of a communication network. Embodiments herein enable the network operator to collect and profile usage information of a subscriber on a User Equipment (UE) with the intention of using the information for revenue maximization applications and preventing fraud for a network operator, wherein revenue maximization applications include but are not limited to fraud management, revenue assurance, churn management, customer experience management, credit risk management and partner settlement.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with PCSK9 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of PCSK9 gene in a cell by genome editing.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN2 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA2). Also provided are materials and methods for editing a ATXN2 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN2 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN2 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN2 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN2 related condition or disorder.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with APOCIII whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of APOCIII gene in a cell by genome editing.

Abstract: Automated determination of web page rendering performance techniques and systems are described. In one example, a web page including multiple user-interactive elements that can be selected or navigated via user input is received. A frame rendering system is employed to automatically identify the user-interactive elements and generate scripts to simulate user input at the user-interactive elements. The generated scripts are then used to simulate user input at the user-interactive elements. The scripts may be generated to simulate user interaction via a variety of different device types, and under a variety of different network conditions. During the simulation, a rendering performance score for the web page is generated by monitoring rendering performance relative to a threshold rendering rate.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with LAMA2, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Merosin-deficient Cogenital Muscular Dystrophy (MDCMD). The present application also provides materials and methods for editing a LAMA2 gene in a cell by genome editing. The present application also provides materials and methods for altering a contiguous genomic sequence of a LAMA2 gene in a cell. In addition, the present application provides one or more gRNAs for editing a LAMA2 gene. The present application also provides a therapeutic comprising at least one or more gRNAs for editing a LAMA2 gene. In addition, the present application provides a therapeutic for treating a patient with a LAMA2 related condition or disorder.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Primary Hyperoxaluria Type 1 (PH1). The present application also provides materials and methods for editing an AGXT gene in a cell by genome editing. The present application also provides materials and methods for altering a contiguous genomic sequence of an AGXT gene in a cell. In addition, the present application provides one or more gRNAs for editing an AGXT gene. The present application also provides a therapeutic comprising at least one or more gRNAs for editing an AGXT gene. In addition, the present application provides a therapeutic for treating a patient with an AGXT related condition or disorder.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with SNCA whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Early Onset Parkinson's Disease (PARK1). Also provided are materials and methods for editing a SNCA gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a SNCA gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a SNCA gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a SNCA gene. In addition, the present disclosure provides therapeutics for treating patients with a SNCA related condition or disorder.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with COL7A1 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Dystrophic Epidermolysis Bullosa (DEB). Also provided are materials and methods for editing a COL7A1 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a COL7A1 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a COL7A1 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a COL7A1 gene. In addition, the present disclosure provides therapeutics for treating patients with a COL7A1 related condition or disorder.

Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo. In addition, the present disclosure provides materials and methods for editing and/or modulating the expression of SOD1 gene in a cell by genome editing.

Abstract: Methods, systems, and computer programs are presented for optimizing data delivery for a User Interface (UI) to a plurality of device types. One method includes operations for receiving at a server a request for an update to the UI of a client device, and for determining, by an orchestrator at the server, modules associated with the request, each module being presented on the UI. Further, the method includes operations for invoking domain services based on the determined modules (each domain service returning respective domain service data), and for synthesizing the domain service data to generate module data for each module. The synthesizing includes selecting from the domain service data and combining the selected domain service data to generate the module data. The module data is transmitted to the client device for all the modules, the module data being processable by the client device to update modules of the UI.